ArticleOncology letters2016
Drug resistance analysis of gefitinib-targeted therapy in non-small cell lung cancer.
Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Rhein Inhibits the Progression of Chemoresistant Lung Cancer Cell Lines via the Stat3/Snail/MMP2/MMP9 Pathway.BioMed research international · 2022Article
- Physicochemical Characterization and Biopharmaceutical Evaluation of ZWF: A Novel Anticancer Drug for the Treatment of Non-small Cell Lung Cancer.AAPS PharmSciTech · 2021Article
- Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells.International journal of molecular sciences · 2020Article
- Precision medicine in gastric cancer.World journal of gastrointestinal oncology · 2019Review
- Astragaloside IV Inhibits the Progression of Non-Small Cell Lung Cancer Through the Akt/GSK-3β/β-Catenin Pathway.Oncology research · 2019Article
- [Thioridazine Sensitizes Apoptotic Effect of TRAIL in Human Lung Cancer PC9 Cells Through ER Stress Mediated Up-regulation of DR5].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2017Article
- Comparison of Gefitinib in the treatment of patients with non-small cell lung cancer and clinical effects of Osimertinib and EGFR Gene mutation.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was to examine the drug resistance analysis of gefitinib-targeted therapy in non-small cell lung cancer (NSCLC). In total, 156 NSCLC patients without surgical treatment were selected, including 117 cases of adenocarcinoma (75%), to receive single gefitinib 0.25 g/day or combined with platinum chemotherapy. Computed tomography was used to evaluate tumor growth for the response and non-response groups. The chemotherapy regimen was changed or combined with radiotherapy in the non-response group. Tumor progression or metastasis in the response group was considered as the generation of drug resistance. The chemotherapy regimen was altered in the response group. Eleven cases had tumor response in the non-response group after the chemotherapy regimen was adjusted (20%), 33 cases had complete response (CR) (32.7%), 44 cases had partial response (PR) (43.6%), and 24 cases had stable disease (SD) (23.8%) in the response group. The drug resistance rates of CR, PR, and SD showed no significant difference (P>0.05). However, the drug-resistant time of CR was significantly delayed and the difference was statistically significant (P<0.05). The response rates of CR, PR, and SD patients regaining the response rate showed no statistical significance after the chemotherapy regimen was adjusted, and the difference was not statistically significant (P>0.05). In conclusion, gefitinib-targeted therapy in NSCLC showed certain drug resistance, which may not be related to the response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.